605 results on '"Satoh, Takefumi"'
Search Results
2. Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer
3. Predictive Value of the Prostate-Specific Antigen Doubling Time for the Effectiveness of Metastasis-Directed Radiotherapy in Patients with Oligometastases after Radical Treatment for Non-metastatic Prostate Cancer: A Single Institution Retrospective Study
4. Real-world data on the comprehensive genetic profiling test for Japanese patients with metastatic castration-resistant prostate cancer
5. Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer
6. Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study
7. Microsomal prostaglandin E synthase-1 promotes lung metastasis via SDF-1/CXCR4-mediated recruitment of CD11b+Gr1+MDSCs from bone marrow
8. Abiraterone Acetate Therapy for mCRPC in Japanese Men
9. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer
10. Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases
11. Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival
12. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
13. Dosimetric Predictors of Toxicity after Prostate Stereotactic Body Radiotherapy: A Single-Institutional Experience of 145 Patients
14. Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
15. A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
16. Postmortem radiation safety and issues pertaining to permanent prostate seed implantation in Japan
17. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial
18. A Prospective Quasi-Randomized Comparison of Intraoperatively Built Custom-Linked Seeds Versus Loose Seeds for Prostate Brachytherapy
19. Combined therapeutic effects of adenoviral vector-mediated GLIPR1 gene therapy and radiotherapy in prostate and bladder cancer models
20. Impact of five‐tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high‐dose‐rate brachytherapy
21. Immuno-gene Therapy for Metastatic Prostate Cancer
22. Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer ( nmCRPC ) patients
23. PD22-05 COMPARISON OF LOW-DOSE-RATE BRACHYTHERAPY VERSUS RADICAL PROSTATECTOMY IN PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER: A PROPENSITY-MATCHED MULTI-INSTITUTIONAL STUDY
24. Therapeutic Potential of Adenovirus Mediated Interleukin-12 Gene Therapy for Prostate Cancer
25. Diffusion-weighted imaging of local recurrent prostate cancer after radiation therapy: comparison with 22-core three-dimensional prostate mapping biopsy
26. Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS)
27. Deaths within 12 months after 125I implantation for brachytherapy of prostate cancer: An investigation of radiation safety issues in Japan (2003–2010)
28. Association between Preoperative Erectile Dysfunction and Prostate Cancer Features—An Analysis from the Duke Prostate Center Database
29. Matched-pair analysis and dosimetric variations of two types of software for interstitial permanent brachytherapy for prostate cancer
30. Comparative Effectiveness Of Low-Dose-Rate Brachytherapy Alone Or Combined With External-Beam Radiotherapy In Intermediate-Risk Prostate Cancer: A Propensity-Matched Multi-Institutional Study
31. Direct Comparison of Low-Dose-Rate Brachytherapy Versus Radical Prostatectomy Using the Surgical Definition of Biochemical Recurrence for Patients with Intermediate-Risk Prostate Cancer
32. Additional file 1 of Direct comparison of low-dose-rate brachytherapy versus radical prostatectomy using the surgical definition of biochemical recurrence for patients with intermediate-risk prostate cancer
33. Comparison of Prophylactic Naftopidil, Tamsulosin, and Silodosin for 125I Brachytherapy–Induced Lower Urinary Tract Symptoms in Patients With Prostate Cancer: Randomized Controlled Trial
34. Factors Predicting Early and Late Phase Decline of Sexual Health‐Related Quality of Life Following Radical Prostatectomy
35. Radiation‐Induced Erectile Dysfunction Using Prostate‐Confined Modern Radiotherapy in a Rat Model
36. Effects of ellipsoid prostate deformation on dose delivery during permanent interstitial brachytherapy
37. Prevalence of Fluoroquinolone-resistant Escherichia coli Before and Incidence of Acute Bacterial Prostatitis After Prostate Biopsy
38. RADIOTHERAPY FOR PROSTATE IN MEN WITH METASTATIC PROSTATE CANCER: A PROPENSITY-SCORE MATCHING ANALYSIS: PD28-08
39. Conceptual assessment of HRQOL among Japanese non‐metastatic castration‐resistant prostate cancer (nmCRPC) patients.
40. Differences between intraoperative ultrasound-based dosimetry and postoperative computed tomography-based dosimetry for permanent interstitial prostate brachytherapy
41. Morphology of hypoxia following cryoablation in a prostate cancer murine model: Its relationship to necrosis, apoptosis and, microvessel density
42. Unmet needs in non-metastatic castration-resistant prostate cancer from the Japanese patient perspective: a discrete choice experiment
43. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer
44. Genitourinary Toxicity After High-Dose-Rate (HDR) Brachytherapy Combined With Hypofractionated External Beam Radiotherapy for Localized Prostate Cancer: An Analysis to Determine the Correlation Between Dose–Volume Histogram Parameters in HDR Brachytherapy and Severity of Toxicity
45. A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
46. A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy
47. Predictive factors for overall quality of life in patients with advanced cancer
48. EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy
49. 14-3-3 Protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid
50. Distribution of Lymphatic Vessel Network in Normal Urinary Bladder
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.